

Medication for Adolescents and Young Adults With Opioid Use Disorder.

Title: Medication for Adolescents and Young Adults With Opioid Use Disorder.

Publication year: 2021

Journal: The Journal of adolescent health : official publication of the Society for Adolescent Medicine

Society: European Society of Cardiology

Origin country: International (Europe)

Target countries: Europe

DOI: 10.1016/j.jadohealth.2020.12.129

PMID: 33485735

Source: <https://pubmed.ncbi.nlm.nih.gov/33485735/>

J Adolesc Health J Adolesc Health 319 nihpa 9102136 The Journal of adolescent health : official publication of the Society for Adolescent Medicine 1054-139X 1879-1972 pmc-is-collection-domain yes pmc-collection-title NIHPA Author Manuscripts PMC7902443 PMC7902443.1 7902443 7902443 NIHMS1658033 33485735 10.1016/j.jadohealth.2020.12.129 NIHMS1658033 NIHPA1658033 1 Article Medication for Adolescents and Young Adults with Opioid Use Disorder Hadland Scott E. MD, MPH, MS 1 2 Aalsma Matthew C. PhD 3 Akgül Sinem MD, PhD 4 Alinsky Rachel H. MD, MPH 5 Bruner Ann MD 6 Chadi Nicholas MD, MPH, FRCPC, FAAP 7 Galagali Preeti M MD, PGDAP, FIAP 8 Kreida Ellen C. LICSW, MPH 9 Robinson Camille A. MD, MPH 5 Wilson J. Deanna MD, MPH 10 1. Grayken Center for Addiction and Department of Pediatrics, Boston Medical Center, One Boston Medical Center Place, Boston, MA, 02118, USA 2. Division of General Pediatrics, Department of Pediatrics, Boston University School of Medicine, 801 Albany Street, Room 2055, Boston, MA, 02119, USA 3. Adolescent Behavioral Health Research Program, Department of Pediatrics, Indiana University, 410 West 10th Street, Suite 1001, Indianapolis, IN, 46202, USA 4. Hacettepe University Faculty of Medicine, Department of Pediatrics, Division of Adolescent Medicine, Ankara, Turkey, 06100 5. Johns Hopkins University School of Medicine, Division of General Pediatrics and Adolescent Medicine, Rubenstein Child Health Building, 200 N. Wolfe Street, Room 2085, Baltimore, MD, 21287, USA 6. Mountain Manor Treatment Center, 3800 Frederick Ave, Baltimore, MD, 21229, USA 7. Division of Adolescent Medicine, Department of Pediatrics, Sainte-Justine University Hospital Center, 3175 Chemin de la Côte-Sainte-Catherine, Montréal, QC, Canada, H3T 1C5 8. Bangalore Adolescent Care and Counselling Centre, 528, 2nd block Rajainagar, Bangalore 560010, India 9. Department of Psychiatry, Boston Medical Center, 850 Harrison Avenue, 9 th Floor, Boston, MA, 02118, USA 10. University of Pittsburgh School of Medicine, University of Pittsburgh School of Medicine, Divisions of General Internal Medicine and Adolescent and Young Adult Medicine, 3420 Fifth Avenue, Pittsburgh, PA, 15213, USA Send correspondence to: Scott E. Hadland, MD, MPH, MS, Grayken Center for Addiction / Department of Pediatrics, Boston Medical Center, 801 Albany Street, Room 2055, Boston, MA, 02118, Phone: 617-414-3681, Fax: 617-414-3679, scott.hadland@bmc.org 21 1 2021 3 2021 68 3 376028 632 636 07 01 2021 01 03 2022 01 03 2022 25 02 2021 06 08 2024 This file is available for text mining. It may also be used consistent with the principles of fair use under the copyright law. Opioid-related morbidity and mortality has risen in many settings globally. It is critical that practitioners who work with adolescents and young adults provide timely, evidence-based treatment for opioid use disorder. Such treatment should include medications for opioid use disorder (MOUD), including buprenorphine, naltrexone, and methadone. Medication treatment is associated with reduced mortality, fewer relapses to opioid use, and enhanced recovery and retention in addiction care, among other positive health outcomes. Unfortunately, the vast majority of adolescents and young adults with opioid use disorder do not receive medication. The Society for Adolescent Health and Medicine recommends that adolescents and young adults be offered medications for opioid use disorder as a critical component of an integrated treatment approach. Barriers to receipt of medications are widespread; many are common to high-, middle-, and low-income countries alike, whereas others differ. Such barriers should be minimized to ensure equitable access to

youth-friendly, affirming, and confidential addiction treatment that includes medications for opioid use disorder. Robust education on opioid use disorder and medication treatment should be provided to all practitioners who work with adolescents and young adults. Strategies to reduce stigma surrounding medication—and stigma experienced by individuals with substance use disorders more generally—should be widely implemented. A broad research agenda is proposed with a goal of expanding the evidence base for the use and delivery of medications for opioid use disorder for adolescents and young adults.

Over the last two decades, opioid-related overdose mortality among adolescents and young adults (AYAs) has increased dramatically [1 , 2]. Although rising overdose mortality in North America has received much attention, mortality is substantially higher in low- and middle-income countries [2]. Opioid use disorder (OUD) commonly begins during adolescence and young adulthood [3], and compromises not only safety and well-being, but also healthy development among AYAs [4].

Providing early, effective treatment for OUD is critical to preventing worsening addiction and the potential for lifelong harm. Evidence-based medications for OUD (MOUD) include buprenorphine, naltrexone, and methadone, and are associated with reduced mortality, fewer relapses to opioid use, and enhanced recovery and retention in addiction care [5 – 13]. However, the majority of AYAs who need treatment for OUD do not receive it [14 – 17]. After receiving a diagnosis of OUD or experiencing overdose, most AYAs only receive behavioral health services if they receive any treatment at all, which places them at risk for overdose and worsening, severe addiction [6 , 18].

This Position Paper advocates for improving receipt of MOUD among AYAs by addressing health systems barriers, workforce limitations, stigma, and research gaps. Throughout, the term MOUD (i.e., “medications for opioid use disorder”) is used rather than the term “medication-assisted treatment”, which implies that medications are an adjunct to OUD care, rather than a critical component of therapy. Though the focus of this paper is on treatment, the utmost importance of prevention efforts should also be highlighted.

Positions were compiled after examining existing clinical guidelines, including those from (alphabetically) the American Academy of Pediatrics [4]; American Society of Addiction Medicine [19]; British Columbia Centre for Substance Use [16]; Indian Psychiatric Society [20]; New South Wales, Australia [15]; United States Substance Abuse and Mental Health Services Administration [21]; and World Health Organization [22]; as well as reviewing clinical trials and observational studies.

Clinical trial and high-quality observational data strongly support the use of MOUD. Treatment with buprenorphine or methadone, which are opioid agonists, or with naltrexone, an opioid antagonist, is associated with fewer opioid cravings, withdrawal, and relapses, and enhanced recovery and retention in addiction care [5 – 13]. Furthermore, retention in buprenorphine or methadone treatment is associated with reduced mortality [5].

Treatment should generally include MOUD in combination with behavioral therapy, though AYAs who do not pursue behavioral therapy should not be denied MOUD [4 , 15 , 16 , 19 – 22]. MOUD may be most effective if provided as early as possible in the development of OUD to prevent worsening severity [4 , 6]. Since OUD carries high risk for mortality, MOUD should not be delayed while waiting to determine whether non-pharmacologic treatment alone is successful. Although buprenorphine, naltrexone, and methadone are not approved for use among adolescents under 18 in all countries, clinical guidelines nonetheless recommend use for AYAs who meet criteria for OUD without age limitations [4 , 15 , 16 , 19 – 22].

Pharmacologic treatment is part of a broader care continuum extending from substance use prevention; screening, brief intervention, and referral to treatment; comprehensive addiction treatment with pharmacologic and non-pharmacologic components; overdose prevention and treatment, including use of naloxone; harm reduction; to long-term recovery support [4 , 16 , 19].

Ideally, these care continuum components are provided alongside other services, including primary care and mental health treatment, to optimize whole health. Ensuring this full spectrum of services requires that practitioners partner whenever possible with family members, other trusted adults in AYAs' lives, and other professionals (e.g., teachers, employers, faith leaders, community-based organizations, law enforcement, and criminal justice agencies) operating outside traditional medical settings (e.g., schools, places of employment, other community settings, and prisons/jails).

Worldwide, AYAs and their families encounter substantial barriers when seeking MOUD [23]. Among the most concerning barriers are United States policies specifically designed to limit medication access. Federal laws require that physicians complete eight hours of training, and nurse practitioners and physician assistants complete 24 hours of training, prior to receiving a waiver (commonly known as the "X waiver") to prescribe buprenorphine. Federal policies also stipulate that adolescents under 18 must demonstrate two prior attempts at treatment that did not involve MOUD before being permitted to initiate methadone. Furthermore, methadone for OUD treatment can only be dispensed by a federally certified opioid treatment program, and availability of such programs that serve adolescents is exceedingly rare [6 , 18]. This is in contrast with Canada and some European countries (e.g., France, Germany, Norway, Luxembourg, Croatia and Belgium) where opioid agonists can be provided by general office-based practitioners without such restrictions [24]. Similar to the US, other European countries have regulations on who can prescribe buprenorphine and methadone.

Other barriers worldwide include requirements for prior authorizations for buprenorphine and naltrexone, insufficient number of addiction treatment programs that offer MOUD to AYAs, lack of health insurance among AYAs, high copays for medications and clinical visits, and pervasive and persistent disparities in offered treatment and access to healthcare by race and ethnicity [25 – 27]. These striking disparities are linked to the complex intersection of historical injustices, culture, and policies [26 , 28].

MOUD provision is often hampered by the common misperception that AYAs should first have a trial of behavioral therapy that does not include pharmacotherapy, or worse, should not receive medications at all [29]. Such beliefs are in opposition to clinical practice guidelines and clinical trial data highlighting that MOUD is associated with reduced mortality and improved treatment outcomes with or without counseling [4 , 15 , 16 , 19 – 22]. Some settings may lack confidential, youth-friendly medical and mental health services, and minors may not be allowed to consent to their own addiction treatment or use of MOUD. Even when AYAs do consent to their treatment, insurance claims that disclose their OUD diagnosis to a parent may threaten confidentiality. In some countries, certain MOUD formulations are not currently available (e.g., long-acting injectable naltrexone is not available for OUD treatment in Canada, and buprenorphine and methadone are not available in Russia).

In specific contexts, such as in criminal justice settings, MOUD access is often highly limited or specific medications (e.g., long-acting injectable naltrexone) are preferred over others (e.g., buprenorphine or methadone), thus preventing AYAs from being offered the full range of evidence-based medications [30]. Individuals involved with criminal justice systems are at high risk of death; the prevalence of OUD is high among incarcerated individuals and overdose mortality within two weeks of release is 129 times higher than in the general population [31]. Yet, exceedingly few incarcerated individuals receive OUD treatment [32]. The full continuum of care should be provided to AYAs in criminal justice settings [31 , 32]. Indeed, alternatives to incarceration should be sought for nonviolent drug-related offenses involving AYAs [30]. Although addiction is frequently viewed as a moral failing, it is more accurately considered a medical condition; as such, AYAs with OUD should receive treatment and recovery support, rather than punishment [30 , 31].

Many geographical regions—particularly rural areas and those with a higher percentage of indigenous people—lack sufficient practitioners with competency treating OUD. Given low insurance reimbursement for addiction treatment services, few financial incentives draw new

practitioners into the OUD treatment workforce. Last, stigma—both against people who use substances, as well as against MOUD use itself—prevents many AYAs from accessing care and receiving evidence-based treatment [33], which is discussed in depth below. Low- and middle-income countries experience many or all of these same barriers to MOUD and other unique barriers [23]. Access to healthcare generally and addiction treatment specifically may be limited. The cost of MOUD, even if available, may be prohibitive.

Given the exceptionally high mortality of OUD, these myriad systemic and access barriers to MOUD place AYAs at great risk [5]. Historically, when such barriers have been removed, the number of individuals receiving MOUD has increased and overdose mortality has improved. A compelling real-world example is that of France, which in 1995 began allowing physicians to prescribe buprenorphine without special training or licensure. Within four years, the number of individuals of all ages receiving buprenorphine increased more than threefold and overdose deaths decreased by nearly 80% [23].

Prescribing barriers such as the buprenorphine waiver requirement in the United States should be eliminated, as should guidelines and policies requiring that AYAs attempt a trial of behavioral treatment alone before providing MOUD [4 , 15 , 16 , 19 – 22]. Policies that result in preference of one medication over another should be abolished, allowing AYAs equal access to buprenorphine, naltrexone, and methadone [19 , 34]. The decision to choose one medication over another should be made by AYAs, their family members, and clinicians, rather than by restrictive policies.

Addiction services should be confidential, welcoming, and culturally-sensitive, like other AYA services in which sensitivity and affirmation are critical to providing excellent care (e.g., reproductive healthcare, mental healthcare, care of lesbian/gay/bisexual/transgender/queer/questioning youth). AYAs should be allowed to consent for their own addiction treatment, including MOUD, though it should be noted that treatment is more likely to be effective with the involvement of a parent or other trusted adult [4]. Reimbursement for addiction treatment should have parity with that of other medical conditions.

A clear treatment gap exists whereby most individuals with OUD do not receive evidence-based treatment; this gap is even greater for AYAs [4 , 6 , 14 , 18]. Practitioners who have both addiction medicine expertise and competency treating AYAs are relatively rare. In the United States, the country with the largest addiction medicine workforce, of all physicians who have completed buprenorphine waiver training, only 2% are pediatricians [personal communication, American Academy of Addiction Psychiatry, 2019]. Even though this Position Paper recommends that the buprenorphine waiver requirement be eliminated, while it exists, it is critical that physicians, nurse practitioners, and physician assistants who work with AYAs receive training in order to immediately expand the workforce.

More broadly, however, practitioners from all disciplines who work with AYAs—including physicians, nurse practitioners, physician assistants, pharmacists, nurses, social workers, and psychologists—should receive stronger training in the management of OUD. Such training should include a focus on MOUD as part of comprehensive treatment. More than this, however, training should foster the development of skills beyond simply prescribing, including but not limited to screening, diagnosis, behavioral interventions, management of comorbid mental health conditions, and involving and supporting family members. By fostering competency in addiction among interdisciplinary practitioners, the AYA-focused workforce can ensure there is no ‘wrong door’ through which AYAs can enter to receive OUD treatment. To ensure a continued workforce pipeline of practitioners comfortable treating AYAs, professional training programs also must begin to educate their learners on addiction.

Stigma against people living with addiction is rampant and detrimental [33]. Such stigma is commonplace in healthcare settings and prevents individuals from seeking needed help. There is additional stigma faced by people on MOUD, who may receive messaging from their own families and communities that being on an opioid agonist such as buprenorphine or methadone is simply

'replacing one addiction with another,' or that someone on MOUD is 'not really in recovery.' Since the hallmark of OUD is ongoing use of opioids despite experiencing negative consequences, such statements are inappropriate because MOUD helps people with OUD reduce or eliminate the negative consequences of their substance use. Nonetheless, the stigma surrounding MOUD is even further amplified for AYAs, who may receive such deleterious messaging from trusted and otherwise well-meaning adults in their lives [29]. As a chronic medical condition, OUD often requires long-term treatment with MOUD. Although the optimal length of treatment for AYAs has not been thoroughly studied, in older adults, longer periods of MOUD receipt are associated with reduced mortality [5].

Given the respect that healthcare practitioners often have in their communities, they should partner with public health and other community officials to support messaging and education in support of MOUD and of people living with OUD. To battle stigma in their own clinical practices, practitioners should ensure youth-friendly, trauma-informed, culturally sensitive, and judgment-free treatment spaces to promote treatment-seeking among AYAs. They should use appropriate language to describe MOUD, such as "pharmacotherapy" or "medications" rather than "replacement therapy". "Medication-assisted treatment" is also an outdated term that is counterproductive to normalizing use of pharmacotherapy [29]; such terminology is not used for other chronic medical conditions (e.g., insulin use in diabetes mellitus is simply referred to as "treatment", rather than "medication-assisted treatment"), and should be avoided in OUD treatment. It is critical that practitioners help AYAs, families, and other trusted adults understand the rationale for pharmacotherapy to battle these common stigmatizing statements [29 , 33].

Practitioners should also use person-first language. For example, they should describe AYAs with OUD as "a person with an opioid use disorder," rather than an "addict," a harmful term commonplace in the lay public. Similarly, practitioners should avoid the term "substance abuser" and "substance abuse" in spoken and written communication, since these terms are associated with stigma in healthcare settings [33 , 35]. Indeed, the term "substance abuse" has been removed from the latest edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5).

Despite clinical guidelines [4 , 15 , 16 , 19 – 21], clinical trial data [7 , 8 , 10 – 13], and high-quality observational studies (e.g., [5 , 6]) that support the use of MOUD in AYAs, much remains unknown [34]. Key questions that should drive a research agenda include (but are not limited to): What is the efficacy, effectiveness, and cost-effectiveness of each MOUD in the treatment of AYAs?

What are best practices to incorporate AYA and family preferences into medication choice?

What is the optimal duration of treatment with MOUD, and does this vary by medication?

What are the most effective models of MOUD delivery in different settings, including primary care and tertiary care (including pediatric hospital settings), and what are alternative modes of delivery (e.g., telemedicine, mobile clinics, and other community-based services)?

What are strategies to incentivize practitioners who work with AYAs to more routinely offer MOUD?

Mortality among AYAs from OUD is rising and expanding access to MOUD is a central strategy to confronting this critical problem. The urgency of achieving the goals in this Position Paper cannot be overstated. Practitioners caring for AYAs have a unique opportunity to provide developmentally appropriate treatment that includes MOUD, and are well positioned to confront the challenge of improving the health and well-being of youth with OUD. Many practitioners already manage other complex conditions with biologic and behavioral components. Perhaps no other workforce is better poised to address the complexities of OUD and ensure that addiction is treated early in the life course to avert decades of potential harm.

Dr. Hadland was supported by the United States (US) National Institute on Drug Abuse (K23DA045085, K23DA045085-S1, and L40DA042434), and the Thrasher Research Fund Early Career Award. Drs. Alinsky and Robinson were supported by the US Eunice Kennedy Shriver National Institute of Child Health and Human Development (T32HD052459) and the US Health Resources and Services Administration Leadership Education in Adolescent Health training grant (T71MC08054). Dr. Wilson was supported by the US National Center for Advancing Translational Sciences (KL2TR001856). Dr. Aalsma was supported by the US National Institute for Drug Abuse (UG1DA050070).

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Conflict of Interest: Dr. Bruner's spouse works as a paid consultant for Alkermes. All other co-authors have no conflicts of interest to disclose.

30392731 10.1016/S2215-0366(18)30337-7 PMC6251968 [2] Bahji A , Cheng B , Gray S , Mortality Among People With Opioid Use Disorder: A Systematic Review and Meta-analysis . J Addict Med 2020 . 10.1097/ADM.0000000000000606 32011406 [3] Substance Abuse and Mental Health Services Administration Center for Behavioral Health Statistics and Quality . Treatment Episode Data Set (TEDS): 2005–2015 . National Admissions to Substance Abuse Treatment Services . BHSIS Series S-91, HHS Publication No. (SMA) 17–5037 Rockville, MD : Substance Abuse and Mental Health Services Administration ; 2017 . [4] Committee on Substance Use and Prevention . Medication-assisted treatment of adolescents with opioid use disorders . Pediatrics 2016 ; 138 : e20161893 . 27550978 10.1542/peds.2016-1893 [5] Sordo L , Barrio G , Bravo MJ , Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies . BMJ 2017 ; 357 : j1550 . 28446428 10.1136/bmj.j1550 PMC5421454 [6] Hadland SE , Bagley SM , Rodean J , Receipt of Timely Addiction Treatment and Association of Early Medication Treatment With Retention in Care Among Youths With Opioid Use Disorder . JAMA Pediatr 2018 ; 172 : 1029 – 37 . 30208470 10.1001/jamapediatrics.2018.2143 PMC6218311 [7] Marsch LA , Moore SK , Borodovsky JT , A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults . Addict Abingdon Engl 2016 ; 111 : 1406 – 1415 . 10.1111/add.13363 PMC4940230 26918564 [8] Marsch LA , Bickel WK , Badger GJ , Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial . Arch Gen Psychiatry 2005 ; 62 : 1157 – 1164 . 16203961 10.1001/archpsyc.62.10.1157 [9] Vo HT , Robbins E , Westwood M , Relapse prevention medications in community treatment for young adults with opioid addiction . Subst Abuse 2016 ; 37 : 392 – 397 . 10.1080/08897077.2016.1143435 26820059 [10] Lee JD , Nunes EV , Novo P , Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial . Lancet Lond Engl 2018 ; 391 : 309 – 18 . 10.1016/S0140-6736(17)32812-X PMC5806119 29150198 [11] Tanum L , Solli KK , Latif Z-E-H , Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence: A Randomized Clinical Noninferiority Trial . JAMA Psychiatry 2017 ; 74 : 1197 – 1205 . 29049469 10.1001/jamapsychiatry.2017.3206 PMC6583381 [12] Krupitsky E , Nunes EV , Ling W , Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial . The Lancet 2011 ; 377 : 1506 – 1513 . 10.1016/S0140-6736(11)60358-9 21529928 [13] Woody GE , Poole SA , Subramaniam G , Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial . JAMA 2008 ; 300 : 2003 – 2011 . 18984887 10.1001/jama.2008.574 PMC2610690 [14] Substance Abuse and Mental Health Services Administration . Key Substance Use and Mental Health Indicators in the United States: Results from the 2018 National Survey on Drug Use and Health (HHS Publication No. PEP19–5068, NSDUH Series H-54) Rockville, MD : Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services Administration ; 2019 . [15] New South Wales Ministry of Health . NSW Clinical Guidelines:

Treatment of Opioid Dependence - 2018 . North Sydney, NSW : New South Wales Ministry of Health ; 2018 . [16] British Columbia Centre on Substance Use, B.C. Ministry of Health, & B.C. Ministry of, Mental Health and Addictions . A Guideline for the Clinical Management of Opioid Use Disorder-Youth Supplement . Vancouver, BC : 2018 . [17] World Health Organization . Information sheet on opioid overdose . Available at : http://www.who.int/substance_abuse/information-sheet/en/ . Accessed March 11, 2020 . [18] Alinsky RH , Zima BT , Rodean J , Receipt of Addiction Treatment After Opioid Overdose Among Medicaid-Enrolled Adolescents and Young Adults . JAMA Pediatr 2020 : e195183 . 10.1001/jamapediatrics.2019.5183 PMC6990723 31905233 [19] American Society of Addiction Medicine , Jarvis M . American Society of Addiction Medicine (ASAM) National Practice Guideline for the Use of Medications in the Treatment of Addiction Involving Opioid Use . Available at : <https://www.asam.org/docs/default-source/quality-science/npg-jam-supplement.pdf> . Accessed March 20, 2020 . 10.1097/ADM.0000000000000166 PMC4605275 26406300 [20] Gaur N , Gautam M , Singh S , Clinical Practice Guidelines on Assessment and Management of Substance Abuse Disorder in Children and Adolescents . Indian J Psychiatry 2019 ; 61 : 333 – 49 . 30745707 10.4103/psychiatry.IndianJPsychiatry_581_18 PMC6345135 [21] Center for Substance Abuse Treatment . Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction Treatment Improvement Protocol (TIP) Series, No. 40 Rockville, MD : Substance Abuse and Mental Health Services Administration ; 2004 . 22514846 [22] World Health Organization . Guidelines for the psychosocially assisted pharmacological treatment of opioid dependence . Available at : <https://apps.who.int/iris/rest/bitstreams/52227/retrieve> . Accessed April 30, 2020 . 23762965 [23] Carrieri MP , Amass L , Lucas GM , Buprenorphine use: the international experience . Clin Infect Dis Off Publ Infect Dis Soc Am 2006 ; 43 Suppl 4 : S197 – 215 . 10.1086/508184 17109307 [24] World Health Organization Regional Office for Europe . How To Improve Opioid Substitution Therapy Implementation . Available at : http://www.euro.who.int/__data/assets/pdf_file/0015/241341/How-to-improve-Opioid-Substitution-Therapy-implementation.pdf . Accessed March 11, 2020 . [25] Mojtabai R , Mauro C , Wall MM , Medication Treatment For Opioid Use Disorders In Substance Use Treatment Facilities . Health Aff Proj Hope 2019 ; 38 : 14 – 23 . 10.1377/hlthaff.2018.05162 PMC6816341 30615514 [26] Barker B , Sedgemore K , Tourangeau M , Intergenerational Trauma: The Relationship Between Residential Schools and the Child Welfare System Among Young People Who Use Drugs in Vancouver, Canada . J Adolesc Health Off Publ Soc Adolesc Med 2019 ; 65 : 248 – 54 . 10.1016/j.jadohealth.2019.01.022 PMC6650326 30948272 [27] Substance Abuse and Mental Health Services Administration . 2017 National Survey on Drug Use and Health: Detailed Tables . HHS Publication No. SMA 17–5044, NSDUH Series H-52 [28] Venner KL , Donovan DM , Campbell ANC , Future directions for medication assisted treatment for opioid use disorder with American Indian/Alaska Natives . Addict Behav 2018 ; 86 : 111 – 7 . 29914717 10.1016/j.addbeh.2018.05.017 PMC6129390 [29] Bagley SM , Hadland SE , Carney BL , Addressing Stigma in Medication Treatment of Adolescents With Opioid Use Disorder . J Addict Med 2017 ; 11 : 415 – 416 . 28767537 10.1097/ADM.0000000000000348 [30] Saloner B , McGinty EE , Beletsky L , A Public Health Strategy for the Opioid Crisis . Public Health Rep Wash DC 1974 2018 ; 133 : 24S – 34S . 10.1177/0033354918793627 PMC6243441 30426871 [31] Binswanger IA , Stern MF , Deyo RA , Release from prison--a high risk of death for former inmates . N Engl J Med 2007 ; 356 : 157 – 65 . 17215533 10.1056/NEJMs064115 PMC2836121 [32] National Institute on Drug Abuse . Treating Opioid Addiction in Criminal Justice Settings . Available at : <https://d14rmgtrwzf5a.cloudfront.net/sites/default/files/policybrief-cj.pdf> . Accessed March 11, 2020 . [33] Botticelli MP , Koh HK . Changing the Language of Addiction . JAMA 2016 ; 316 : 1361 – 1362 . 27701667 10.1001/jama.2016.11874 [34] Ambekar A , Rao R , Agrawal A , Research on opioid substitution therapy in India: A brief, narrative review . Indian J Psychiatry 2018 ; 60 : 265 – 70 . 30405250 10.4103/psychiatry.IndianJPsychiatry_385_18 PMC6201667 [35] Kelly JF , Westerhoff CM . Does it matter how we refer to individuals with substance-related conditions? A randomized study of two commonly used terms . Int J Drug Policy 2010 ; 21 : 202 – 7 . 20005692 10.1016/j.drugpo.2009.10.010 Positions of the Society for Adolescent Health and Medicine: All adolescents and young adults with opioid use disorder should be offered medication as a critical component of an integrated treatment approach that includes pharmacologic and non-pharmacologic strategies.

Barriers to the receipt of medications for opioid use disorder need to be minimized.

Robust education on opioid use disorder treatment should be provided for all practitioners who work with adolescents and young adults.

Strategies to reduce stigma surrounding the use of medications for opioid use disorder among adolescents and young adults should be widely implemented.

Research efforts to expand the evidence base for the use and delivery of medications for opioid use disorder among adolescents and young adults should be supported.